In vitro and in vivo degradation of programmed cell death ligand 1 (PD-L1) by a proteolysis targeting chimera (PROTAC)
出版年份 2021 全文链接
标题
In vitro and in vivo degradation of programmed cell death ligand 1 (PD-L1) by a proteolysis targeting chimera (PROTAC)
作者
关键词
PROTACs, PD-L1, Immunotherapy, BMS-37 derivatives
出版物
BIOORGANIC CHEMISTRY
Volume 111, Issue -, Pages 104833
出版商
Elsevier BV
发表日期
2021-03-20
DOI
10.1016/j.bioorg.2021.104833
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1
- (2020) Binbin Cheng et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer
- (2019) Xin Han et al. JOURNAL OF MEDICINAL CHEMISTRY
- Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK)
- (2019) Xiaotian Kong et al. JOURNAL OF MEDICINAL CHEMISTRY
- Identification of a neo-epitope dominating endogenous CD8 T cell responses to MC-38 colorectal cancer
- (2019) Brett J. Hos et al. OncoImmunology
- Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression
- (2018) Chong Qin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel–Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7
- (2018) Vittoria Zoppi et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeted Degradation of MDM2 as a New Approach to Improve the Efficacy of MDM2-p53 Inhibitors
- (2018) Ryan P. Wurz et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression
- (2018) Yangbing Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- Enhancing Antiproliferative Activity and Selectivity of a FLT-3 Inhibitor by Proteolysis Targeting Chimera Conversion
- (2018) George M. Burslem et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1
- (2017) Katarzyna Guzik et al. JOURNAL OF MEDICINAL CHEMISTRY
- Membrane-Active Hydantoin Derivatives as Antibiotic Agents
- (2017) Ma Su et al. JOURNAL OF MEDICINAL CHEMISTRY
- CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
- (2017) Marian L. Burr et al. NATURE
- Waste disposal—An attractive strategy for cancer therapy
- (2017) Jemilat Salami et al. SCIENCE
- Coinhibitory Pathways in Immunotherapy for Cancer
- (2016) Susanne H. Baumeister et al. Annual Review of Immunology
- Cancer immunotherapy: the beginning of the end of cancer?
- (2016) Sofia Farkona et al. BMC Medicine
- Cancer Immunotherapy: Selected Targets and Small-Molecule Modulators
- (2016) Hilmar Weinmann ChemMedChem
- From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway
- (2016) Mei-Miao Zhan et al. DRUG DISCOVERY TODAY
- Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015)
- (2016) Tryfon Zarganes-Tzitzikas et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
- (2016) Danny N. Khalil et al. Nature Reviews Clinical Oncology
- Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
- (2016) Axel Hoos NATURE REVIEWS DRUG DISCOVERY
- Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)
- (2016) Krzysztof M. Zak et al. Oncotarget
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
- (2015) Padmanee Sharma et al. CELL
- The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
- (2015) Daniel Sanghoon Shin et al. CURRENT OPINION IN IMMUNOLOGY
- Combination cancer immunotherapies tailored to the tumour microenvironment
- (2015) Mark J. Smyth et al. Nature Reviews Clinical Oncology
- Combination cancer immunotherapy and new immunomodulatory targets
- (2015) Kathleen M. Mahoney et al. NATURE REVIEWS DRUG DISCOVERY
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search